

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-32. (Cancelled)

33. (New) A compound, which is
4-ethoxy-6-fluoroquinoline-2-carboxylic acid;
4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyloxy)-2-butenyl]oxy)-6-fluoroquinoline-2-carboxylic acid;
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate; or
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate; or
a pharmaceutically acceptable salt thereof, or
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

34. (New) A compound according to claim 33, which is
4-ethoxy-6-fluoroquinoline-2-carboxylic acid;
4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyloxy)-2-butenyl]oxy)-6-fluoroquinoline-2-carboxylic acid;
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate; or
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate; or
a pharmaceutically acceptable salt thereof.

35. (New) A pharmaceutical composition, comprising a compound of claim 33 and a pharmaceutically acceptable carrier.

36. (New) A pharmaceutical composition, comprising a compound of claim 34 and a pharmaceutically acceptable carrier.

37. (New) A method for treating or preventing a hyperglycaemia-related pathology, which is diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 35.

38. (New) A method according to claim 37, which is for treating diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia.

39. (New) A method for treating or preventing a hyperglycaemia-related pathology, which is diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 36.

40. (New) A method according to claim 39, which is for treating diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia.